Company

Oncoswiss is a Swiss Company founded in 2016 and based in Lugano, Switzerland.

Oncoswiss is focused in co-development of generic cancer treatments dosage forms with leading oncological selected API producers and marketing partners to license-out to leading pharma distributors world-wide.

Oncoswiss’s Management team is comprised of veterans in the pharmaceutical industry with extensive product development experience with long track record, conducting development, clinicals studies, as well as manufacturing of the finished dosage form in the USA and API in Europe.

Companies of the Group

Key facts

Millions of people lack access to essential medicines at affordable prices affecting 90% of the world population.

Oncoswiss is based on a novel business model of profit sharing for co-developing already approved drugs with expired or expiring patents, involving selected exclusive global pharma investment partners to be followed by globalisation of the product after regulatory approval.

Oncoswiss outsources all development work, API route of synthesis development, finished dosage form development, patent landscape for freedom to operate, regulatory registration and legal contracts. Our independent accredited accounting firms are used to assure full transparency to the investing partners.

Oncoswiss also maintains a capability for the development of new routes of synthesis of selected APIs and finished dosage forms to be patented.

Oncoswiss works with selected experienced oncological advisors and consultants in Europe and the USA, and assembles the product development team on a product-by-product basis dependent on the product requirements.

Oncoswiss legal and patent counsels are based Basel-Switzerland, Milan-Italy, Barcelona-Spain as well as Chicago-USA.

Oncoswiss is working to manage the promotion and distribution activities on selected patented products, directly or indirectly, in collaboration with Innovative patent holder for each marketing partner's territories.

Strategic relationship with Eos Biosciences
OncoSwiss has established a strategic relationship with Eos Biosciences (Los Angeles, CA) to access innovative oncology-focused products. Eos Biosciences is developing a proprietary portfolio of patent-protected oncology and immune-oncology products based on their innovative and differentiated biological nanoparticle drug-delivery system, Eosomes. Further information about Eos Biosciences may be found on their web site:
www.eosbiosciences.com

What define us

• Innovative entrepreneurial spirit
• Global vision
• Innovation built on knowledge and experience
• Organization in continuous evolution and motion
• Flexibility, creativity, enthusiasm and high motivation